Daratumumab: Difference between revisions
From IDWiki
mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
| + | * IgG1K human monoclonal antibody targetting CD38 |
||
| − | * Anti-CD38 antibody used in the treatment of [[multiple myeloma]] |
||
| + | * Indications include [[multiple myeloma]] |
||
| ⚫ | |||
| + | * Adverse effects include [[hypertension]] (10%), edema, fatigue, cytopenias including anemia, liver enzyme abnormalities, infusion reactions (35% with first infusion), cytokine release syndrome, anaphylaxis, electrolyte abnormalities, headache (10%), insomnia, cough, dyspnea, rhinitis |
||
| ⚫ | |||
[[Category:Medications]] |
[[Category:Medications]] |
||
Revision as of 11:02, 9 February 2023
- IgG1K human monoclonal antibody targetting CD38
- Indications include multiple myeloma
- Adverse effects include hypertension (10%), edema, fatigue, cytopenias including anemia, liver enzyme abnormalities, infusion reactions (35% with first infusion), cytokine release syndrome, anaphylaxis, electrolyte abnormalities, headache (10%), insomnia, cough, dyspnea, rhinitis
- Risk of infections, including CMV, HSV, and possible hepatitis B
